Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Compare

1,417 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRDN Analyst Ratings

Strong Buy

13 Buy

1 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Viridian

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRDN Stock 12 Month Forecast

Average Price Target

$38.09

▲(60.99% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $38.09 with a high forecast of $61.00 and a low forecast of $14.09. The average price target represents a 60.99% change from the last price of $23.66.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","62":"$62","23.75":"$23.8","36.5":"$36.5","49.25":"$49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.0853621,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,23.75,36.5,49.25,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.27,24.326153846153847,27.38230769230769,30.43846153846154,33.494615384615386,36.550769230769234,39.60692307692308,42.66307692307693,45.719230769230776,48.775384615384624,51.83153846153847,54.88769230769232,57.94384615384615,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.27,22.563846153846153,23.857692307692307,25.15153846153846,26.445384615384615,27.73923076923077,29.033076923076926,30.32692307692308,31.620769230769234,32.91461538461539,34.20846153846154,35.502307692307696,36.79615384615385,{"y":38.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.27,20.717335546153844,20.164671092307692,19.612006638461537,19.059342184615385,18.50667773076923,17.954013276923078,17.401348823076923,16.848684369230767,16.296019915384615,15.743355461538462,15.190691007692308,14.638026553846153,{"y":14.0853621,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$61.00

Average Price Target$38.09

Lowest Price Target$14.09

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Laura Chico

Wedbush

$40→$42

Buy

77.51%

Upside

Reiterated

10/27/25

Strategic Financial Maneuvers and Key Milestones Position Viridian Therapeutics for Growth: A Buy Rating by Laura Chico

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC) and Viridian Therapeutics (NASDAQ: VRDN)

Douglas Tsao

H.C. Wainwright

$34

Buy

43.70%

Upside

Reiterated

10/21/25

Viridian Therapeutics: Strategic Financial Agreement and Promising Product Launches Drive Buy RatingValuation and Risks. Our Buy rating and price target of $34 for Viridian are based on 8.5x our discounted 2035 risk-adjusted revenue estimate of $491M. We adjust each pipeline asset for the probability of success (PoS). We assign a 80% PoS for VRDN-001, as a Phase 3 asset, and 60% for VRDN-003. We currently don’t incorporate Viridian’s earlier assets VRDN-006 and VRDN-008.

David Martin PhD

Bloom Burton

$14.02

Buy

-40.75%

Downside

Reiterated

10/21/25

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Viridian Therapeutics (VRDN)

Leland Gershell

Oppenheimer

$32→$36

Buy

52.16%

Upside

Reiterated

10/21/25

Viridian Therapeutics price target raised to $36 from $32 at OppenheimerViridian Therapeutics price target raised to $36 from $32 at Oppenheimer

Rami Katkhuda

LifeSci Capital

$46

Buy

94.42%

Upside

Reiterated

10/20/25

Viridian Therapeutics: Strategic Royalty Financing and Promising TED Treatment Pipeline Justify Buy RatingThis morning, Viridian (Nasdaq: VRDN) announced a royalty ﬁnancing agreement with DRI Healthcare Acquision LP for up to $300M in nondiluve capital.

Alex Thompson CFA

Stifel Nicolaus

$41

Buy

73.29%

Upside

Assigned

10/20/25

Stifel Nicolaus Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)We are reiterating our Buy Rating on VRDN following the presentation of Ph3 data for Roche's Satralizumab at ASOPRS.

Serge Belanger

Needham

$34

Buy

43.70%

Upside

Reiterated

10/17/25

Viridian Therapeutics Positioned for Success Amid Competitive Challenges in TED MarketWe note that satra's pivotal ph 3 trials mostly consisted of active TED patients and had very few subjects with chronic TED.

Clara Dong

Jefferies

$44

Buy

85.97%

Upside

Reiterated

10/17/25

Viridian Therapeutics: Strong Buy Rating Backed by Superior Efficacy and Strategic Advancements in TED Market

Julian Harrison

BTIG

$61

Buy

157.82%

Upside

Reiterated

09/15/25

Promising Developments and Strategic Advancements Justify Buy Rating for Viridian TherapeuticsWe also expect payors to prefer an SC administered option, and we are not aware of any other publicly announced late-stage development efforts of an SC autoinjector IGF-1R Tx option. If positive, REVEAL-1/2 are expected to support a BLA submission in YE26. The BLA submission for veligrotug is now expected in November 2025 (previously guided to 2H25). Veligrotug has received Breakthrough Therapy Designation, which could support Priority Review, so we could see a commercial launch of veligrotug as early as mid-2026 if Priority Review is granted. VRDN has also strengthened its IP portfolio with the addition of a composition patent for VRDN-003 with term to 2041 and a methods patent for veligrotug with term to 2042.

Gavin Clark-Gartner

Evercore ISI

$38

Buy

60.61%

Upside

Reiterated

08/11/25

Evercore ISI Keeps Their Buy Rating on Viridian Therapeutics (VRDN)

Lisa Walter

RBC Capital

$45→$41

Buy

73.29%

Upside

Reiterated

08/07/25

RBC Capital Remains a Buy on Viridian Therapeutics (VRDN)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Ocular Therapeutix (NASDAQ: OCUL)

Derek Archila

Wells Fargo

$26

Hold

9.89%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments

Kalpit Patel

B. Riley Securities

$19

Hold

-19.70%

Downside

Reiterated

05/21/25

B.Riley reiterates Neutral Rating on Viridian Therapeutic (VRDN)B.Riley analyst Kalpit Patel reiterated a Neutral rating and $19.00 price target on Viridian Therapeutic (NASDAQ: VRDN).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Laura Chico

Wedbush

$40→$42

Buy

77.51%

Upside

Reiterated

10/27/25

Strategic Financial Maneuvers and Key Milestones Position Viridian Therapeutics for Growth: A Buy Rating by Laura Chico

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC) and Viridian Therapeutics (NASDAQ: VRDN)

Douglas Tsao

H.C. Wainwright

$34

Buy

43.70%

Upside

Reiterated

10/21/25

David Martin PhD

Bloom Burton

$14.02

Buy

-40.75%

Downside

Reiterated

10/21/25

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Viridian Therapeutics (VRDN)

Leland Gershell

Oppenheimer

$32→$36

Buy

52.16%

Upside

Reiterated

10/21/25

Viridian Therapeutics price target raised to $36 from $32 at OppenheimerViridian Therapeutics price target raised to $36 from $32 at Oppenheimer

Rami Katkhuda

LifeSci Capital

$46

Buy

94.42%

Upside

Reiterated

10/20/25

Alex Thompson CFA

Stifel Nicolaus

$41

Buy

73.29%

Upside

Assigned

10/20/25

Stifel Nicolaus Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)We are reiterating our Buy Rating on VRDN following the presentation of Ph3 data for Roche's Satralizumab at ASOPRS.

Serge Belanger

Needham

$34

Buy

43.70%

Upside

Reiterated

10/17/25

Clara Dong

Jefferies

$44

Buy

85.97%

Upside

Reiterated

10/17/25

Viridian Therapeutics: Strong Buy Rating Backed by Superior Efficacy and Strategic Advancements in TED Market

Julian Harrison

BTIG

$61

Buy

157.82%

Upside

Reiterated

09/15/25

Gavin Clark-Gartner

Evercore ISI

$38

Buy

60.61%

Upside

Reiterated

08/11/25

Evercore ISI Keeps Their Buy Rating on Viridian Therapeutics (VRDN)

Lisa Walter

RBC Capital

$45→$41

Buy

73.29%

Upside

Reiterated

08/07/25

RBC Capital Remains a Buy on Viridian Therapeutics (VRDN)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Ocular Therapeutix (NASDAQ: OCUL)

Derek Archila

Wells Fargo

$26

Hold

9.89%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments

Kalpit Patel

B. Riley Securities

$19

Hold

-19.70%

Downside

Reiterated

05/21/25

B.Riley reiterates Neutral Rating on Viridian Therapeutic (VRDN)B.Riley analyst Kalpit Patel reiterated a Neutral rating and $19.00 price target on Viridian Therapeutic (NASDAQ: VRDN).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viridian Therapeutics

1 Month

xxx

Success Rate

15/30 ratings generated profit

Average Return

+4.44%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +4.44% per trade.

3 Months

xxx

Success Rate

15/29 ratings generated profit

Average Return

+7.08%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 51.72% of your transactions generating a profit, with an average return of +7.08% per trade.

1 Year

Laura ChicoWedbush

Success Rate

25/43 ratings generated profit

Average Return

+5.84%

reiterated a buy rating 5 days ago

Copying Laura Chico's trades and holding each position for 1 Year would result in 58.14% of your transactions generating a profit, with an average return of +5.84% per trade.

2 Years

xxx

Success Rate

16/20 ratings generated profit

Average Return

+24.11%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +24.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRDN Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRDN has received 20 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. VRDN average Analyst price target in the past 3 months is 38.09.

Each month's total comprises the sum of three months' worth of ratings.

VRDN Financial Forecast

VRDN Earnings Forecast

Next quarter’s earnings estimate for VRDN is -$1.02 with a range of -$1.30 to -$0.27. The previous quarter’s EPS was -$1.00. VRDN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year VRDN has Preformed in-line its overall industry.

VRDN Sales Forecast

Next quarter’s sales forecast for VRDN is $34.00K with a range of $0.00 to $100.00K. The previous quarter’s sales results were $75.00K. VRDN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year VRDN has Preformed in-line its overall industry.

VRDN Stock Forecast FAQ

What is VRDN’s average 12-month price target, according to analysts?

Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is 38.09.

What is VRDN’s upside potential, based on the analysts’ average price target?

Viridian Therapeutics has 60.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRDN a Buy, Sell or Hold?

Viridian Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.

What is Viridian Therapeutics’s price target?

The average price target for Viridian Therapeutics is 38.09. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $61.00 ,the lowest forecast is $14.09. The average price target represents 60.99% Increase from the current price of $23.66.

What do analysts say about Viridian Therapeutics?

Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of VRDN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

VRDN Analyst Ratings

VRDN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Viridian Therapeutics

VRDN Analyst Recommendation Trends

VRDN Financial Forecast

VRDN Earnings Forecast

VRDN Sales Forecast

VRDN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts